Comunicato Stampa: Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial - transgene

Compatibilità

Salva(0)

Condividi

C. Ottensmeier, et al.
medRxiv
Preprint available on medRxiv website – Download the Article

Menu

Fonte: https://www.transgene.fr/viral-based-individualized-neoantigen-vaccine-as-adjuvant-treatment-in-resected-head-and-neck-squamous-cell-carcinoma-immunogenicity-and-efficacy-from-a-randomized-phase-i-trial/

Recapiti

cat18